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Medications for opioid use disorder
Prisons
Jails
A B S T R A C T
Background: We examined the impact of expanded access to medications for opioid use disorder (MOUD) in a
unified prison and jail system on post-release, opioid-related overdose mortality.
Methods: We developed a microsimulation model to simulate a population of 55,000 persons at risk of opioid-
related overdose mortality in Rhode Island. The effect of an extended-release (XR) naltrexone only intervention
and the effect of providing access to all three MOUD (i.e., methadone, buprenorphine, and XR-naltrexone) at
release from incarceration on cumulative overdose death over eight years (2017–2024) were compared to the
standard of care (i.e., limited access to MOUD).
Results: In the standard of care scenario, the model predicted 2385 opioid-related overdose deaths between 2017
and 2024. An XR-naltrexone intervention averted 103 deaths (4.3% reduction), and access to all three MOUD
averted 139 deaths (5.8% reduction). Among those with prior year incarceration, an XR-naltrexone only in-
tervention and access to all three MOUD reduced overdose deaths by 22.8% and 31.6%, respectively.
Conclusions: Expanded access to MOUD in prison and jail settings can reduce overdose mortality in a general, at-
risk population. However, the real-world impact of this approach will vary by levels of incarceration, treatment
enrollment, and post-release retention.
Introduction
The epidemic of opioid-related overdose mortality is a public health
crisis that continues to evolve across the US. In 2018, there were over
67,000 overdose deaths documented in the US, and approximately 70%
were opioid-involved (Wilson, Kariisa, Seth, Smith & Davis, 2020).
From 2015 to 2016 alone, drug overdose deaths increased by 21%
nationwide, and the emergence of fentanyl in drug markets has con-
tributed to dramatic increases in overdose mortality in several states
(Scholl, Seth, Kariisa, Wilson & Baldwin, 2019).
The risk of opioid-related overdose mortality is particularly acute
among persons with recent incarceration in prisons and jails
(Binswanger et al., 2007; Binswanger, Blatchford, Mueller & Stern,
2013; Merrall et al., 2010). During incarceration, tolerance is dimin-
ished or lost, which places individuals at greatly elevated risk of
overdose upon release (Møller et al., 2010). Disrupted social support
networks, limited or interrupted access to medications for opioid use
disorder (MOUD) in the community, medical comorbidities, and a
variety of other socioeconomic conditions further exacerbate overdose
risk among individuals leaving incarceration (Joudrey et al., 2019). In a
seminal paper, Binswanger et al. found that the first two weeks fol-
lowing release from incarceration were associated with a 129-fold in-
crease in overdose risk relative to the general population
(Binswanger et al., 2007).
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estimation of the simulated population are provided in the
Supplemental Appendix.
At model initialization, agents were ascribed time-varying and time-
fixed characteristics. Gender and injection drug use (IDU) status were
fixed characteristics assigned to each agent in the model, based on es-
timates from the Substance Abuse and Mental Health Data Archive,
statewide data, and existing literature (appendix pp. 5–7). Overdose
mortality risk is expected to vary across the at-risk population, with
some agents being characterized as being lower risk due to underlying
behaviors (e.g., infrequent use, use in small amounts) and some agents
being characterized as higher risk (e.g., homelessness, heavy use, IDU).
We attempt to capture this heterogeneity in underlying overdose risk by
assigning a base risk of opioid-related overdose mortality (px) to four
agent classes (male IDU, male non-IDU, female IDU, and female non-
IDU), which are then influenced by dynamic agent states. In the current
model, IDU status was used as a proxy for increased risk for overdose
mortality over the lifetime of the model (Havens et al., 2011;
Kinner et al., 2012; Mathers et al., 2013).
Dynamic states were determined by probabilities at each discrete
time-step and were informed by statewide data and existing literature
(appendix pp. 8). These dynamic agent states were: (1) underlying
baseline overdose risk in the absence of MOUD or incarceration as-
signed to each agent class, (2) incarceration status (i.e., currently in-
carcerated, post-release, or no prior-year incarceration), and (3) MOUD
status (methadone/buprenorphine, XR-naltrexone, or none). The model
proceeds in a series of two-week discrete time-steps. The micro-
simulation model simulated a discrete-time stochastic model in steady
state, in which agents can exit the model due to death or no longer
being at risk of overdose mortality; the latter exit mechanism was im-
plemented to represent the spontaneous cessation of extra-medical
opioid use.
Agents did not return to the population after exiting the model. To
maintain a steady state, agents exiting the model were replaced by
agents belonging to the same time-invariant agent class (i.e., gender
and IDU status). The model was calibrated to reproduce trajectories
observed in overdose mortality, incarceration, MOUD treatment en-
gagement (both at release from incarceration and overall in the com-
munity) in Rhode Island between 2014 and 2018. Further details re-
garding model calibration (pp. 18), processes, and parameterization are
available in Table 1 and the Supplemental Appendix.
Pathways for agent transitions across dynamic states in the model in
the standard of care (base case) are summarized in Fig. 1. Pathways in
the model are identical for all agent classes; thus, gender and IDU status
are not specified in Fig. 1. In the XR-naltrexone-only scenario, agents
may enter treatment with XR-naltrexone directly from incarceration;
therefore, in a schematic representing the XR-naltrexone-only scenario,
an additional arrow from incarceration to XR-naltrexone would exist. In
the all three MOUD scenario, agents may enter treatment with XR-
naltrexone or methadone/buprenorphine directly from incarceration;
therefore, in a schematic representing the all three MOUD scenario,
additional arrows from incarceration to XR-naltrexone and from in-
carceration to methadone/buprenorphine would exist (see appendix pp.
8).
Opioid-related overdose mortality
Baseline risk for overdose mortality was determined by membership
in both specific time-invariant and dynamic agent classes, with the
relative risk of overdose mortality (px) assigned for IDU males (p1), non-
IDU males (p2), IDU females (p3), and non-IDU females (p4; see ap-
pendix pp. 9). Baseline risk across agent classes was informed by sta-
tewide overdose decedent data (Prevent Overdose RI, 2019c). Agents
that were neither engaged in MOUD nor incarcerated at a given time
step were assigned a baseline relative risk of overdose mortality of px.
We used evidence from two systematic reviews (Degenhardt et al.,
2011; Mathers et al., 2013) and additional literature (Krupitsky et al.,
Increased access to MOUD for persons who are incarcerated is a 
promising approach to reduce mortality and overdose risk following 
release from incarceration (Hedrich et al., 2012; National Academies of 
Sciences & Medicine, 2019). A recent meta-analysis and systematic 
review of the effectiveness of MOUD in prison and jail settings found 
that the provision of MOUD in prisons and jails reduced non-medical 
opioid use and increased treatment entry in the community post-release 
(Moore et al., 2019). While additional medical, social, and economic 
benefits to expanding access to MOUD to persons who are incarcerated 
have been documented (Heimer et al., 2006; Kinlock, Gordon, 
Schwartz, Fitzgerald & O'Grady, 2009; Lee et al., 2016, 2018; 
Rich et al., 2015; Zaller et al., 2013), access to MOUD for persons who 
are incarcerated has been very limited in the US.
In 2016, the Rhode Island Department of Corrections (RIDOC) be-
came the first statewide correctional system in the US to provide 
comprehensive access to MOUD to persons who are incarcerated 
(Clarke, Martin, Gresko & Rich, 2018). The program provides access to 
all three US Food and Drug Administration-approved MOUD (i.e., me-
thadone, buprenorphine, XR-naltrexone), screens all persons who be-
come incarcerated for opioid use disorder, initiates and continues 
MOUD for medically eligible individuals who choose to do so, and 
connects individuals to MOUD providers in the community at release 
(Clarke et al., 2018). Prior to 2016, the standard of care at RIDOC was 
to provide access to methadone only to pregnant women and to in-
dividuals who were enrolled in treatment with methadone immediately 
prior to incarceration—the latter of which was limited to an approxi-
mately 30-day taper protocol (Clarke et al., 2018). The pre-2016 
standard of care in Rhode Island represents an important base of 
comparison from a policy-making perspective, as limited MOUD access 
in prison and jail settings is a national norm (Vestal, 2018).
Providing access to all three MOUD to incarcerated persons is a 
demonstrated overdose prevention approach, but the long-term, 
broader impact on overdose mortality in the larger at-risk population is 
unknown. In this study, microsimulation modeling was used to quantify 
the potential effect of expanded MOUD access in a combined prison and 
jail setting on overdose mortality in a population of at-risk persons in 
Rhode Island, USA, a state with a high burden of overdose mortality 
(i.e., an estimated 25.9 opioid overdose deaths per 100,000 in 2018)
(Wilson et al., 2020). Microsimulation modeling is an ideal methodo-
logical approach for the current research question because it permits 
evaluation of multiple counterfactual scenarios that could not be im-
plemented concurrently and compared in the real world 
(Arnold, Harrison, Heppenstall & Gilthorpe, 2019). This type of mod-
eling is useful from a policymaking standpoint because it provides 
evidence for the long-term, population-level impact of public health 
interventions. The primary objective of this study was to measure the 
potential effect of providing MOUD access in a combined prison and jail 
setting on overdose mortality among all persons at risk of overdose in 
Rhode Island over eight years, as compared to an XR-naltrexone only 
intervention and the pre-2016 standard of care in the correctional 
setting.
Methods
Model setting and structure
Opioid-related overdose mortality over an 8-year period 
(2017–2024) was modeled using microsimulation. The model run 
period was constrained to 8 years to minimize future uncertainty while 
providing long-term projections that may be useful for policymaking. 
Agents in the model (n = 55,000) represent a population of individuals 
aged 13 and older in Rhode Island who are at risk of opioid overdose 
mortality. We defined persons at risk of opioid-related overdose mor-
tality as all those residing in Rhode Island who used any opioid extra-
medically in the prior year and persons enrolled in treatment with 
MOUD in the prior year. Additional details regarding construction and
2011; Larochelle et al., 2018) to define the relative risk of overdose
mortality during periods of MOUD enrollment, which was set to 0.4px
and 0.2px for those enrolled in treatment with methadone/buprenor-
phine and XR-naltrexone, respectively. Based on prior literature, the
relative risk of overdose mortality increased following MOUD dis-
continuation was set to 2px and 8px at 2 weeks post-discontinuation for
those enrolled in methadone/buprenorphine and XR-naltrexone, re-
spectively; the relative risk of overdose mortality then returned to 1px
for a given agent thereafter. The relative risk of overdose mortality also
increased following release from incarceration to 108px at 2 weeks post
incarceration, then declined with time to 1px over the course of one
year (see appendix pp. 9). The influence of dynamic agent states on
baseline risk of overdose mortality across agent classes is summarized
in Fig. 2.
Incarceration
The model proceeds in 2-week time-steps; therefore, incarceration
was defined as being incarcerated in Rhode Island's unified prison and
jail system for a period of at least 2 weeks. At each time-step, the mean
distribution of agents who were incarcerated was as follows: 60.6% of
non-IDU males, 27.8% of IDU males, 9.7% of non-IDU females, and
Table 1.




Population size n = 55,000 Calculated using data from the Substance Abuse and Mental Health Data
Archive: 2-Year Restricted-use Data Analysis System (2015–2016)
(Substance Abuse & Mental Health Data Archive, 2015–2016)
Sex & IDU status Distribution of male non-IDU (49.1%), male IDU (14.5%),
female non-IDU (32.7%), and female IDU (3.6%) at risk of
opioid-related mortality (age 13+)
Calculated using data from the Substance Abuse and Mental Health Data
Archive: 2-Year Restricted-use Data Analysis System (2015–2016)
(Substance Abuse & Mental Health Data Archive, 2015–2016); relevant
literature (Fingerhood, King, Brooner & Rastegar, 2014); and publicly
available aggregate statewide MOUD utilization data
(Prevent Overdose RI, 2019b)
Opioid-related overdose mortality
Base risk The base risk of opioid related overdose mortality (px) was
stratified by agent class (i.e., gender and IDU status).
Overdose mortality then varies according to dynamic agent
states, including MOUD enrollment vs. discontinuation status
and incarceration recency.
Informed by publicly available aggregate statewide overdose data from
the Rhode Island Department of Health (Rhode Island Department of
Health, 2019), calibrated
Release from incarceration 108p at 2 weeks post-incarceration and then degrades with time
(see appendix pp. 9)
Informed by publicly available aggregate statewide overdose data from
the Rhode Island Department of Health (Rhode Island Department of
Health, 2019) and relevant literature (Binswanger et al., 2013, 2007;
Merrall et al., 2010), calibrated
XR-naltrexone discontinuation 8p at 2 weeks post-discontinuation Informed by relevant literature (Digiusto et al., 2004; Gibson et al., 2007;
Saucier, Wolfe & Dasgupta, 2018), calibrated
Methadone/buprenorphine
discontinuation
2p at 2 weeks post-discontinuation Informed by relevant literature (Sordo et al., 2017), calibrated
Methadone/buprenorphine
enrollment
0.4p while engaged in treatment Informed by relevant literature (Degenhardt et al., 2011; Mathers et al.,
2013), calibrated
XR-naltrexone enrollment 0.2p while engaged in treatment Informed by relevant literature (Krupitsky et al., 2011; Larochelle et al.,
2018), calibrated
Incarceration
Incarceration Proportion of at risk population incarcerated per 2-week
timestep: 955/55,000 = 1.7%
Informed by Rhode Island Department of Corrections reports
(Rhode Island Department of Corrections, 2017) and relevant literature
(Lam et al., 2019), calibrated
Sentence duration Female distribution: 40% 2–4 weeks, 47.5% 5–26 weeks, 6.5%
27–52 weeks, 4.5% 53–156 weeks (6 years), 1.5% > 6 years
Male distribution: 43% 2–4 weeks, 50% 5–26 weeks, 2% 27–52,
2% 53–156 (6 years), 3% > 6 years.
Informed by Rhode Island Department of Corrections reports
(Rhode Island Department of Corrections, 2017), calibrated
Recidivism risk (3-year) Varies by male (51%) vs. female (36%) agent class Informed by Rhode Island Department of Corrections reports
(Rhode Island Department of Corrections, 2017)
MOUD
MOUD initiation in the community
(by agent class)
Probability of initiating MOUD in the community at each time-
step (applies to all scenarios): female non-IDU (1.25%), male
non-IDU (1.1%), female IDU (8.1%), male IDU (14.9%)
Informed by publicly available statewide MOUD utilization data
(Prevent Overdose RI, 2019b) and estimates from Substance Abuse and
Mental Health Services Administration (SAMHSA) (Substance Abuse &
Mental Health Data Archive, 2015–2016) to achieve steady state
MOUD initiation in the community
(by medication type)
Among those initiating MOUD, probability of initiating: XR-
naltrexone (0.8%), methadone/buprenorphine (99.2%).
Applies to all scenarios
Informed by publicly available aggregate statewide MOUD utilization
data (Prevent Overdose RI, 2019b)
MOUD initiation at RIDOC (by
medication type)
Standard of care scenario: XR-naltrexone (0%), methadone/
buprenorphine (0%). XR-naltrexone only scenario: XR-
naltrexone (66%), methadone/buprenorphine (0%).
All three MOUD scenario: XR-naltrexone (0.8%), methadone/
buprenorphine (99.2%)
Informed by publicly available aggregate statewide MOUD utilization





Distribution: 2 weeks (6.7%), 4 weeks (6.2%), 6 weeks (4%), 8
weeks (4%), 12 weeks (8.2%), 18 weeks (6.5%), 26 weeks
(10.6%), 52 weeks (18.8%), ≥2 years (35%). Median duration:
52 weeks
Informed by SAMHSA Treatment Episode Data Set – Discharges (TEDS-D),
2016 Rhode Island and relevant literature (Lee et al., 2016, 2018)
XR-naltrexone distribution of
treatment duration
Distribution: 4 weeks (45%), 8 weeks (10%), 12 weeks (9%), 18
weeks (8%), 26 weeks (8%), ≥1 year (20%). Median duration:
8 weeks
Informed by SAMHSA Treatment Episode Data Set – Discharges (TEDS-D),
2016 Rhode Island and relevant literature (Lee et al., 2016, 2018)
1.9% of IDU females. This distribution was informed by RIDOC data
and relevant literature (see appendix pp. 12–13). Recidivism risk was
assigned according to agent class, with male agents and female agents
having a 51% and 36% probability (respectively) of becoming re-in-
carcerated within 3-years following a given release from incarceration
event. The distribution of sentence duration was informed by published
RIDOC annual reports (appendix pp. 13). The probability of in-
carceration was held constant over time and did not differ by IDU or
prior or current treatment status. During periods of incarceration, the
probability of overdose mortality was fixed to be zero due to the low
incidence of overdose mortality among persons incarcerated at the
RIDOC.
Medications for opioid use disorder (MOUD)
The probability of initiating MOUD in the community was de-
termined by agent class and remained the same across all three sce-
narios (Table 1). Among those initiating MOUD in the community,
99.2% were assigned to initiate methadone/buprenorphine and 0.8%
were assigned to initiate XR-naltrexone; the percent initiating metha-
done/buprenorphine vs. XR-naltrexone was defined using publicly
available, statewide, yearend 2016 treatment data
(Prevent Overdose RI, 2019b). While MOUD enrollment has increased
in Rhode Island in recent years (Prevent Overdose RI, 2019b), it is
unclear whether these marginal increases are driven by recent struc-
tural changes (e.g., Medicaid expansion in 2014) that would not impact
trends in MOUD enrollment in the long-term. Given this uncertainty,
the number of agents engaged in MOUD treatment in the community
was calibrated to a steady state target informed by statewide data to
ensure conservative model estimates. The distributions of methadone/
buprenorphine and XR-naltrexone treatment duration were informed
by the SAMHSA Treatment Episode Data Set – Discharges (TEDS-D) and
prior literature (appendix pp. 14–15). Six weeks after initiating treat-
ment, 55.0% of individuals on XR-NTX and 83.1% of individuals on
methadone or buprenorphine are retained in treatment. Treatment re-
tention then declines to 20.0% and 53.8% at one year post-treatment
initiation, respectively.
Fig. 1. Pathways for agent transition across dynamic states in the model,
standard of care base case.
Fig. 2. Influence of dynamic agent states on base risk of opioid-related overdose mortality across agent classes
N(ote: IDU = injection drug use; XR-naltrexone = extended-release naltrexone).
that year, 324 overdose deaths were observed statewide, and 10%
(n = 32) were observed among persons with prior-year incarceration.
In our all three MOUD scenario, 28 cumulative overdose deaths oc-
curred among agents with prior-year incarceration occurred during the
first year of the simulation, accounting for 11% of all overdose deaths in
the model.
This analysis did not require oversight from an institutional review
board, as the model relied on publicly available, aggregate data.
Sensitivity analyses
Sensitivity analyses were conducted to assess the robustness of the
primary analyses to uncertain model parameters that were likely to
affect the observed impact of all three MOUD and XR-naltrexone only
interventions at RIDOC; these parameters included retention in MOUD
following release from incarceration, the percent of incarcerated per-
sons who were initiated on MOUD and XR-naltrexone only following
release from incarceration, overdose mortality risk during treatment
with XR-naltrexone and methadone/buprenorphine, overdose risk fol-
lowing discontinuation of XR-naltrexone, and total population size.
Parameters were considered sensitive to change if modification by +/-
25% from their base value produced a greater than 10% deviation in
opioid-related overdose death relative to the standard of care scenario.
Results
The microsimulation model predicted that the greatest number of
opioid-related overdose deaths would be observed in the standard of
care scenario. In the standard of care scenario, the model predicted a
cumulative number of 2385 opioid-related overdose deaths among the
at-risk population in Rhode Island over the eight-year period (95% SI:
2301–2477), and a cumulative number of 423 (95% SI: 386–462)
opioid-related overdose deaths among agents with prior-year in-
carceration during the same period (Table 2). The model produced
relatively constant rates of opioid overdose deaths, such that the annual
mortality rate in the total at-risk population was estimated to be 5.42
per 1000 person-years (95% SI: 5.23–5.63).
Our model predicted that, relative to the standard of care scenario,
reductions in opioid-related overdose mortality would be observed in
both the XR-naltrexone only scenario and the all three MOUD scenario,
though the greatest reductions were observed in the latter. In the entire
at-risk population, the model predicted a cumulative number of 103
deaths averted over the eight-year period in the XR-naltrexone only
scenario (95% SI: 20–187); this corresponds to a 4.3% population-level
reduction relative to the base case over the eight-year period (95% SI:
0.8–7.8%). In the same population, the model predicted a cumulative
number of 139 deaths averted over the eight-year period in the all three
MOUD scenario (95% SI: 53–214), corresponding to a 5.8% reduction
in the at-risk population (2.2–9.0%).
Among agents with prior-year incarceration, the model predicted a
cumulative number of 326 overdose deaths over the eight-year period
in the XR-naltrexone only scenario (95% SI: 293–360); this corresponds
to approximately 12 deaths averted per year (95% SI: 8–16) and a
22.8% reduction in overdose death relative to the base case (95% SI:
Cumulative number of opioid-related overdose deaths, deaths averted, and percent reduction in deaths among all persons at risk in Rhode Island and among persons
at risk with prior-year incarceration from 2017 to 2024 in the standard of care scenario, an extended release (XR)-naltrexone only scenario, and an all three
medications for opioid use disorder (MOUD) scenario.
Among all persons at risk Among those with prior-year incarceration












Standard of care 2385 (2301–2477) – – 423 (386–462) – –
XR-naltrexone only 2282 (2198–2365) 103 (20–187) 4.3 (0.8–7.8) 326 (293–360) 96 (63–130) 22.8 (14.9–30.7)
All three MOUD 2245 (2171–2332) 139 (53–214) 5.8 (2.2–9.0) 289 (255–320) 134 (103–168) 31.6 (24.3–39.7)
Using de-identified RIDOC treatment enrollment data from 2016, 
we confirmed that less than 1% of persons who initiate MOUD are 
enrolled in treatment with XR-naltrexone at release; therefore, in the all 
three medications scenario, the current distribution of treatment allo-
cation in the community was used (Prevent Overdose RI, 2019b), with 
99.2% assigned to initiate methadone/buprenorphine and 0.8% as-
signed to initiate XR-naltrexone.
Model scenarios
Three scenarios were assessed in the main analyses: (1) standard of 
care (i.e., methadone provision to pregnant women and a 30-day taper 
protocol for individuals currently enrolled in methadone at time of 
incarceration), (2) only XR-naltrexone offered at RIDOC, and (3) all 
three MOUD offered at RIDOC. In the standard of care scenario, no 
agents were assigned to community-based MOUD in the time-step fol-
lowing release from incarceration. In the XR-naltrexone-only scenario, 
66% of agents were assigned to community-based treatment with XR-
naltrexone in the time-step following release from incarceration. This 
XR-naltrexone initiation rate was informed by prior research suggesting 
that approximately 66% of persons eligible for treatment with MOUD 
will opt to initiate XR-naltrexone in the absence of alternative treat-
ment with MOUD (Di Paola et al., 2014). In the all three MOUD sce-
nario, 100% of agents were assigned to community-based treatment 
with MOUD in the time-step following release from incarceration. All 
other parameters and processes were held constant across model sce-
narios. Each model scenario was simulated for 1000 iterations.
Outcome measures
The primary outcomes were the cumulative overdose mortality over 
8 years (2017–2024) in the entire at-risk population and the associated 
percent reduction in overdose mortality relative to the standard of care. 
As a secondary outcome, for each scenario, we also examined the cu-
mulative number of opioid-related overdose deaths among agents with 
prior-year incarceration. All outcome measures were stratified by agent 
class and incarceration status. Estimates are presented with 95% si-
mulation intervals (SIs) to reflect model stochasticity (i.e., 1000 itera-
tions for each model scenario).
Calibration of main outcome measures
In the standard of care scenario, opioid-related overdose mortality 
for both the entire at-risk population and for agents with prior-year 
incarceration was calibrated to steady state. The primary calibration 
targets for the model were the observed overdose mortality rates in 
Rhode Island in 2015. In that year, 290 opioid-related overdose deaths 
were observed statewide, and 51 overdose deaths occurred among 
persons with prior-year incarceration (Prevent Overdose RI, 2019a). In 
our standard of care scenario, the calibrated model produced 280 cu-
mulative overdose deaths during the first year of the simulation, and 44 
of those deaths were among agents with prior-year incarceration.
In the all three MOUD scenario, calibrated model output was fairly 
consistent with observed overdose mortality in Rhode Island in 2017. In
Table 2.
Australian study underscores the importance of post-release retention
in care, as those who were retained in treatment with methadone and
buprenorphine were compared to those who were not. In the present
study, our sensitivity analyses found that increased retention in treat-
ment corresponded with greater reductions in overdose mortality. Im-
proved systems to promote post-release retreatment in MOUD may
yield even greater reductions in opioid-related overdose mortality post-
release than those predicted in the current model. Additionally, in the
present study, we also model reductions in overdose mortality with
access to XR-naltrexone, which was not evaluated in the England and
Australian settings described above and may limit comparability.
Due to characteristics that are unique to Rhode Island, the present
study likely underestimates the potential reduction in overdose mor-
tality that would be observed if XR-naltrexone only or all three MOUD
were implemented in correctional facilities elsewhere. First, at yearend
2016, Rhode Island had the third lowest incarceration rate in the
country (Kaeble & Cowhig, 2018). While pre-arrest diversion to treat-
ment with MOUD is likely to produce similar reductions in overdose
mortality without the harms that are associated with incarceration
(Freudenberg & Heller, 2016), those jurisdictions that incarcerate a
greater proportion of persons at risk of opioid-related overdose mor-
tality should expect to see greater reductions in overdose mortality than
those projected in Rhode Island. Second, the presence of diversion
programming in Rhode Island, which offers the dismissal of criminal
charges to those with nonviolent felonies through participation in drug
treatment and mental health programs, may produce underestimates in
the potential reduction in overdose mortality that may be observed
elsewhere. Third, both the XR-naltrexone only and the all three MOUD
scenarios in this model were compared to the pre-2016 standard of care
in Rhode Island, which allowed for the provision of methadone on a 30-
day taper protocol among those who were prescribed methadone prior
to incarceration (Clarke et al., 2018). In the majority of prisons and jails
in the US, access to MOUD is limited to women who are pregnant.
Therefore, for most correctional facilities, the proportion of persons
who would newly become eligible for MOUD with the implementation
of either XR-naltrexone only or all three MOUD would be greater than
the proportion of those who became eligible in Rhode Island. As a re-
sult, many jurisdictions could observe even greater reductions in
overdose mortality relative to the previous standard of care than those
projected in the current model.
Several limitations to our study warrant further investigation to
ensure the validity of our model. First, the impact of an XR-naltrexone
only intervention and an all three MOUD intervention varies with the
level of treatment coverage and post-release retention in care achieved.
While these factors were varied in the sensitivity analyses, it is im-
portant to note that the true treatment coverage and post-release
treatment retention is difficult to ascertain and has important im-
plications on the impact of both approaches. Care should be taken in
transporting our model projections to other settings, as differences in
MOUD availability and accessibility in the community may exist.
Second, the implementation of an XR-naltrexone only intervention and
an all three MOUD intervention are the only approaches explicitly
modeled in this simulation; the model does not account for other harm
reduction approaches or mitigating factors that might influence over-
dose risk behaviors or overdose mortality in the modelled population,
such as naloxone distribution at release from incarceration and/or
changes in the illicit drug market. Third, Rhode Island is a unique
setting with a low overall level of incarceration, and the predictions
made in the present model may not be representative of other locations.
Fourth, heterogeneity in overdose risk in the underlying at-risk popu-
lation has not been fully captured, as we were unable to identify suf-
ficient data to further stratify overdose risk within agent classes (e.g.,
“high risk non-IDU male” vs “low risk non-IDU male”); however, we
were able to calibrate overdose mortality across four agent classes using
observed trends in Rhode Island, which is why these four strata were
chosen. As such, we are confident in the overdose mortality estimates
14.9–30.7). In the same population, the model predicted a cumulative 
number of 289 overdose deaths over the eight-year period in the all 
three MOUD scenario (95% SI: 255–320), corresponding to approxi-
mately 17 deaths averted per year (95% SI: 13–21) and a 31.6% re-
duction in overdose deaths relative to the base case (95% SI: 
24.3–39.7%).
Sensitivity analyses
The effects of the XR-naltrexone only intervention and the all three 
MOUD intervention were sensitive to the percentage of agents suc-
cessfully linked to MOUD immediately following release from in-
carceration, with greater reductions in overdose mortality observed 
with higher percentages of agents linked to post-release treatment with 
MOUD (S8 Figure). These findings were also sensitive to post-release 
retention in treatment, with greater reductions in overdose mortality 
observed with higher treatment retention (S8 Figure). The percentage 
of agents successfully linked to MOUD and post-release retention in 
treatment were modulated concurrently across 50 analyses: 25 combi-
nations were each explored in the XR-naltrexone only scenario and in 
the all three MOUD scenario. In the all three MOUD scenario, when 
retention in treatment was held at baseline level and the proportion of 
incarcerated agents released on treatment was increased to 100%, we 
observed a 32% decrease in overdose deaths. When the proportion of 
incarcerated agents released on treatment was held at 0%, a two-fold 
increase in retention in treatment produced a 10% reduction in over-
dose deaths. Findings were comparable in the XR-naltrexone only sce-
nario (S8 Figure).
Overdose mortality risk during treatment with XR-naltrexone and 
methadone/buprenorphine (S9 Figure and S10 Figure), overdose risk 
following discontinuation of XR-naltrexone (S11 Table), and total po-
pulation size (S12 Table) were not sensitive to change.
Discussion
This study is the first to estimate the potential population-level 
impact of increased access to MOUD in correctional settings on opioid-
related overdose mortality in an at-risk population. Our model predicts 
that providing access to all three MOUD in a correctional setting has a 
greater impact on overdose mortality in the community and within an 
at-risk population as compared to a XR-naltrexone only intervention. 
Relative to the standard of care, XR-naltrexone alone reduced overdose 
mortality by 22.8% among those with prior-year incarceration, while 
providing access to all three MOUD reduced overdose mortality by 
31.6% among those with prior-year incarceration over the simulated 
eight year period.
Findings in the present study are consistent with those found in a 
national prospective observational study that evaluated the impact of 
increased access to methadone and buprenorphine in English prisons on 
overdose mortality post-release. Investigators in England documented a 
31% reduction in drug-related poisoning deaths following release from 
incarceration among those who received methadone or buprenorphine 
while incarcerated as compared to those who did not (Marsden et al., 
2017). While important differences between England and the Rhode 
Island setting exist, consistency between these estimates suggest that 
the reduction in overdose mortality projected in the current model are 
both realistic and attainable. Nonetheless, findings in the present study 
are conservative as compared to retrospective data linkage study that 
evaluated the impact of increased access to methadone and buprenor-
phine in Australian prisons on overdose mortality post-release. In-
vestigators in New South Wales, Australia, documented a 74% reduc-
tion in accidental drug-induced deaths following release from 
incarceration when comparing those who received methadone or bu-
prenorphine while incarcerated and were retained in treatment post-
release as compared to those who had not (Degenhardt et al., 2014). 
The greater reduction in post-release overdose deaths attained in the
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across these strata. Fifth, IDU status is a fixed (rather than dynamic) 
agent state in the current model because we were unable to identify 
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from non-IDU to IDU) in Rhode Island. At the individual level, some 
modulation between IDU states would be expected; however, im-
plementing these individualized transitions in the absence of data 
would introduce error in model estimates at the population-level and 
reduce model validity. Sixth, the distribution of sentence lengths that 
were implemented in this model were calibrated to all persons in-
carcerated in Rhode Island, of whom, approximately a third are esti-
mated to be at risk of overdose. This is a limitation of the model, as the 
distribution of sentence duration for this population has not yet been 
assessed beyond 6 months (Rich et al., 2015); nonetheless, we believe 
that these estimates are reasonably representative of those that would 
be observed in the subset of individuals who are at risk of overdose 
were these measured and calculated in the real world. Seventh, there is 
some evidence of an increased risk of opioid-related overdose mortality 
during the initial two-week induction phase onto treatment with me-
thadone that is not explicitly reflected by model processes (Sordo et al., 
2017). Nonetheless, we believe that this period of increased risk is 
captured in our parameterization of the overall risk of opioid-related 
overdose mortality during treatment with methadone/buprenorphine, 
which was also informed by systematic reviews (Degenhardt et al., 
2011; Mathers et al., 2013). Finally, while local data were used to 
parameterize the model whenever possible, several input parameters 
were derived from multiple sources, which could introduce bias and 
adversely affect the accuracy and generalizability of the model outputs.
Providing access to all three MOUD in prisons and jails has the 
potential to avert more opioid-related overdose death than the pre-
2016 standard of care in Rhode Island or providing access to XR-nal-
trexone alone, which has poorer long-term treatment adherence and 
higher mortality rates after treatment discontinuation. The predicted 
impact of either approach varies with treatment coverage and post-re-
lease treatment retention. Therefore, jurisdictions that have limited 
MOUD treatment capacity in the community should expand both cor-
rections-based and community-based MOUD treatment concurrently.
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